U.S. Patent and Trademark Office Upholds the Validity of MonoSol Rx’s US Patent No. 8,765,167 in the Face of Multiple Inter Partes Review Challenges Brought by BioDelivery Sciences International, Inc. (BDSI)

WARREN, N.J., April 7, 2016 – MonoSol Rx, a specialty pharmaceutical company leveraging its PharmFilm® drug delivery technology to improve patient outcomes and to address unmet needs, today announced that the U.S. Patent and Trademark Office (USPTO) has upheld the validity of all challenged claims in U.S. Patent No. 8,765,167 (the ‘167 patent). The challenges to the ‘167 patent were asserted in four Inter Partes Review (IPR) proceedings brought by BioDelivery Sciences International, Inc. (Nasdaq: BDSI, “BDSI”) against MonoSol Rx.

One IPR was denied institution in May 2015, and the rehearing request on that IPR was denied by the USPTO in November of 2015. Even more significantly, the three remaining IPR challenges were decided in final written decisions issued by the USPTO on March 24, 2016, wherein the USPTO upheld the validity of the claims in the ‘167 patent, which is entitled “Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions.” The ‘167 patent has a priority date as far back as 2001, as well as additional priority in 2005.

“The PTO’s confirmation of the validity of our ‘167 patent is an important victory for MonoSol Rx and for our proprietary, patented PharmFilm technology,” said A. Mark Schobel, Chief Innovation and Technology Officer of MonoSol Rx. “Now that these issues relating to the ‘167 patent have been decided, we will continue to aggressively assert this patent and others against those companies that infringe our intellectual property. At the same time, MonoSol Rx looks forward to quickly and reasonably resolving all outstanding and potential infringement matters related to the claims in the ‘167 and related patents. We remain confident in the strength of our entire portfolio of intellectual property and in the pioneering work we have done in the area of film-based drug delivery.”

About MonoSol Rx
MonoSol Rx is a specialty pharmaceutical company leveraging its proprietary PharmFilm drug delivery technology to develop products that improve patient outcomes and address unmet needs. PharmFilm can benefit patients by improving the efficacy, safety, and convenience of pharmaceutical and over-the counter products. MonoSol Rx's leadership in film drug delivery is supported by strong IP protection, a robust pipeline of prescription drug formulations, and two FDA-approved products — Suboxone® (buprenorphine and naloxone) sublingual film and Zuplenz® (ondansetron) oral soluble film. For press releases and other company information, visit www.monosolrx.com. More information about PharmFilm can be found at www.pharmfilm.com.

Please complete this form:

  • To subscribe to receive information updates about products and services from Aquestive Therapeutics, or to receive information about Aquestive-sponsored clinical trials, please check the box below. Please also review our privacy policy, which describes how we use and process your data. You may also contact us at any time by emailing info@aquestive.com or by calling 1-908-941-1900.
  • This field is for validation purposes and should be left unchanged.

Please complete the form below and click SEND to receive a copy of “Overcoming Solubility and Permeability Challenges,” a case study detailing the achievements made by Aquestive’s formulation team to create the diazepam buccal film.

  • To subscribe to receive marketing updates about diazepam buccal film and other products and services from Aquestive, please complete the form below. Please also review our privacy policy, which describes how we use and process your data. You may also contact us at any time by emailing busdev@aquestive.com.

Please complete the form to receive a demonstration kit for our PharmFilm® technology.

  • To subscribe to receive marketing updates about our PharmFilm® technology and other products and services from Aquestive, please complete the form below. Please also review our privacy policy, which describes how we use and process your data. You may also contact us at any time by emailing busdev@aquestive.com.

Please complete this form:

  • To subscribe to receive marketing updates about products and services from Aquestive Therapeutics, or to receive information about Aquestive-sponsored clinical trials, please check the box below. Please also review our privacy policy, which describes how we use and process your data. If for any reason you no longer wish to receive information on Aquestive-sponsored clinical trials, you can contact us at any time by emailing clinicaltrials@aquestive.com.

Whether we are partnering to out license our PharmFilm® technology or in-licensing adjacent assets, Aquestive works hand-in-hand with our partners to address their toughest clinical and business challenges. To learn more, please complete the following form:

  • To subscribe to receive information updates about products and services from Aquestive Therapeutics, or to receive information about Aquestive-sponsored clinical trials, please check the box below. Please also review our privacy policy, which describes how we use and process your data. You may also contact us at any time by emailing busdev@aquestive.com.

Please complete the form below and click submit to receive a copy of “The Art of LGS Book.”

Please complete our short form to speak with a business development specialist.